Population
Patients with advanced chronic obstructive pulmonary disease and right-sided heart failure
Design
Review
Authors
Loading...
Warrants RCTs of targeted PH therapies in COPD; leaves open clinical adoption pending efficacy data.
This review highlights the pathophysiology of pulmonary hypertension in COPD, emphasizing extensive vascular remodeling, and discusses the potential future role of pharmacological treatments such as prostacyclin derivatives, endothelin antagonists, and inhaled nitric oxide.
Naeije et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: